CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers

Genes Chromosomes and Cancer

Volumn 51, Issue 2, 2012, Pages 186-195

  Chen, Junwei ^a   Guo, Tianhua ^a   Zhang, Lei ^a   Qin, Li Xuan ^a   Singer, Samuel ^a   Maki, Robert G ^b   Taguchi, Takahiro ^c   Dematteo, Ronald ^a   Besmer, Peter ^a   Antonescu, Cristina R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD44V6 ANTIGEN; CELL MARKER; IMATINIB;

ARTICLE; CANCER STEM CELL; FLOW CYTOMETRY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD44; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; INFANT; NEOPLASTIC STEM CELLS; PEPTIDES; SARCOMA; SIDE-POPULATION CELLS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 83055186465     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20942     Document Type: Article

References (31)

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR. 2007. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13: 170-181.
2. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. 2005. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190.
3. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, Nilsson O. 2011. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer 129: 1149-1161.
4. Bozzi F, Conca E, Manenti G, Negri T, Brich S, Gronchi A, Pierotti MA, Tamborini E, Pilotti S. 2011. High CD133 expression levels in gastrointestinal stromal tumors. Cytometry B Clin Cytom 80: 238-247.
5. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. 2004. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942.
6. Chen H, Ordog T, Chen J, Young DL, Bardsley MR, Redelman D, Ward SM, Sanders KM. 2007. Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine. Physiol Genom 31: 492-509.
7. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL. 2010. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
9. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P. 2005. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270-279.
10. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. 1996. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806.
11. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. 2005. A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 4: 203-205.
12. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. 1995. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619.
13. LaBarge MA, Bissell MJ. 2008. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 118: 2021-2024.
14. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. 1997. A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 90: 5013-5021.
15. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M. 2002. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 359: 1301-1307.
16. Orian-Rousseau V. 2010. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277.
17. Pardal R, Clarke MF, Morrison SJ. 2003. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
18. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. 2000. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 192: 427-432.
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
20. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y, Manova K, Antonescu CR, Besmer P. 2006. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 103: 12843-12848.
21. Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C. 2003. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 163: 691-700.
22. Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R. 2010. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 10: 1182-1190.
23. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. 2008. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
24. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
25. Thomas J, Wang L, Clark RE, Pirmohamed M. 2004. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104: 3739-3745.
26. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G. 2009. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446-453.
27. Turley EA, Noble PW, Bourguignon LY. 2002. Signaling properties of hyaluronan receptors. J Biol Chem 277: 4589-4592.
28. Weigmann A, Corbeil D, Hellwig A, Huttner WB. 1997. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 94: 12425-12430.
29. Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q. 2011. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci USA 108: 1591-1596.
30. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
31. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J. 2010. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078.